# Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath Tumor

> **NCT07743554** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Girish Dhall, MD** · enrollment: 23 (estimated)

## Conditions studied

- MPNST (Malignant Peripheral Nerve Sheath Tumor)

## Interventions

- **DRUG:** avutometinib capsule + defactinib tablet

## Key facts

- **NCT ID:** NCT07743554
- **Lead sponsor:** Girish Dhall, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01-01
- **Primary completion:** 2031-01
- **Final completion:** 2032-01
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2026-08-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07743554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07743554, "Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath Tumor". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07743554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*